Lightlake Therapeutics Announces Partnership with National Institute on Drug Abuse (NIDA) to Treat Opioid Overdose

LONDON, Aug. 21, 2013 /PRNewswire/ -- Lightlake Therapeutics Inc., ("Lightlake" or the "Company") (OTC BB: LLTP), a biopharmaceutical company developing addiction treatments based on its expertise in opioid antagonists, announced today the Company is moving forward in expanding access to medication for the treatment of opioid overdose with the National Institute on Drug Abuse ("NIDA"), part of the National Institutes of Health ("NIH"). This fall, NIDA will sponsor a two-week clinical study designed to evaluate the pharmacokinetic properties of Lightlake's intranasal naloxone application in 14 healthy volunteer subjects.

Naloxone is an injectable medicine that can rapidly reverse the overdose of prescription and illicit opioids. Lightlake is working on a new intranasal delivery system for the delivery of naloxone that could widely expand its availability and use in preventing opioid overdose deaths, a public health problem of epidemic proportion in the U.S. According to the Centers for Disease Control and Prevention, 16,651 people died from prescription opioid overdose in the U.S. in 2010, a significant increase from the 4,030 overdose deaths in 1999.

Assuming favorable outcomes from this study, NIDA plans to file an IND for a larger study. The expected goal of this partnership is to have an FDA approved intranasal naloxone solution for the reversal of opioid overdoses that can be brought to market within 12 to 18 months.

"Naloxone is a lifesaving drug used in an emergency to treat patients who have overdosed on opioids such as heroin or oxycodone. It's proven to be very safe and has been used for decades," said Dr. Roger Crystal, CEO of Lightlake Therapeutics. "The problem is that it's not readily available and only approved for administered through injection. We are working with NIDA to create an intranasal delivery system that can make naloxone much easier to use and more accessible for first responders, paramedics and families and friends of addicts who are at risk of overdose."

About Lightlake Therapeutics

Lightlake Therapeutics Inc., a London-based biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative solutions to common addictions and related disorders. The Company holds patents covering the use of intranasal naloxone to treat Binge Eating Disorder ("BED") as well as patents covering addiction to drugs including cocaine, amphetamine, and MDMA. Lightlake is currently focused on advancing its treatment for BED, which has successfully completed Phase II clinical trials, and a Phase II trial is planned for the indication of Bulimia Nervosa. Lightlake is also applying its technology to develop a treatment for managing the complications of opioid drug addiction in collaboration with the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health. For more information please visit: http://www.lightlaketherapeutics.com

Forward Looking Statement

This press release contains forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," estimates," "predicts," "projects," "potential" or "continue" or the negative of such terms and other comparable terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors. These and other factors may cause our actual results to differ materially from any forward- looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this presentation to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Media Contacts:
KCSA Strategic Communications
Anne Donohoe / Taylor McGann
+1 212.896.1261 / +1 212.896.1253
[email protected] / [email protected]

Investor Contacts:
KCSA Strategic Communications
Philip Carlson / Josh Dver
+1 212.896.1233 / +1 212.896.1239
[email protected] / [email protected]

SOURCE Lightlake Therapeutics Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED